Consistently, inhibition of the BRAFV600E in human melanoma cell lines using the specific inhibitor PLX-4032 (vemurafenib) resulted in substantial decrease in the expression of the downstream BRAF target phopho-ERK 1/2 as expected but also in GLI1 further confirming that GLI1 being a target of MAPK signaling pathway and that MAPK and SHH-GLI pathway do interact with each other in melanoma. This evidence concerns the gene BRAF and melanoma.